-
1
-
-
0001340091
-
-
Y. Takebayashi, K. Yamada, K. Miyadera, T. Sumizawa, T. Furukawa, F. Kinoshita, D. Aoki, H. Okumura, Y. Yamada, S. Akiyama, and T. Aikou, Eur. J. Cancer, 1996, 32 A, 1227.
-
(1996)
Eur. J. Cancer
, vol.32 A
, pp. 1227
-
-
Takebayashi, Y.1
Yamada, K.2
Miyadera, K.3
Sumizawa, T.4
Furukawa, T.5
Kinoshita, F.6
Aoki, D.7
Okumura, H.8
Yamada, Y.9
Akiyama, S.10
Aikou, T.11
-
2
-
-
0027125627
-
-
T. Furukawa, A. Yoshimura, T. Sumizawa, M. Haraguchi, and S. Akiyama, Nature, 1992, 356, 668;
-
(1992)
Nature
, vol.356
, pp. 668
-
-
Furukawa, T.1
Yoshimura, A.2
Sumizawa, T.3
Haraguchi, M.4
Akiyama, S.5
-
3
-
-
23444455766
-
-
M. Haraguchi, K. Miyadera, K. Uemura, T. Sumizawa, T. Furukawa, K. Yamada, and S. Akiyama, Nature, 1994, 368, 198.
-
(1994)
Nature
, vol.368
, pp. 198
-
-
Haraguchi, M.1
Miyadera, K.2
Uemura, K.3
Sumizawa, T.4
Furukawa, T.5
Yamada, K.6
Akiyama, S.7
-
4
-
-
34250206317
-
-
V. A. McNally, M. Rajabi, A. Gbaj, I. J. Stratford, P. N. Edwards, K. T. Douglas, R. A. Bryce, M. Jaffar, and S. Freeman, J. Pharm. Pharmacology, 2007, 59, 537.
-
(2007)
J. Pharm. Pharmacology
, vol.59
, pp. 537
-
-
McNally, V.A.1
Rajabi, M.2
Gbaj, A.3
Stratford, I.J.4
Edwards, P.N.5
Douglas, K.T.6
Bryce, R.A.7
Jaffar, M.8
Freeman, S.9
-
5
-
-
0014197030
-
-
P. Langen, G. Etzgold, D. Barwolff, and B. Preussel, Biochem. Pharmacol., 1967, 16, 1833.
-
(1967)
Biochem. Pharmacol.
, vol.16
, pp. 1833
-
-
Langen, P.1
Etzgold, G.2
Barwolff, D.3
Preussel, B.4
-
6
-
-
2942553016
-
-
S. Yano, H. Kazuno, N. Suzuki, T. Emura, K. Wierzba, J. Yamashita, Y. Tada, Y. Yamada, M. Fukushima, and T. Asao, Bioorg. Med. Chem., 2004, 12, 3431.
-
(2004)
Bioorg. Med. Chem.
, vol.12
, pp. 3431
-
-
Yano, S.1
Kazuno, H.2
Suzuki, N.3
Emura, T.4
Wierzba, K.5
Yamashita, J.6
Tada, Y.7
Yamada, Y.8
Fukushima, M.9
Asao, T.10
-
7
-
-
0036203013
-
-
K. Nishijima, Y. Kuge, K. Seki, K. Ohkura, N. Motoki, K. Nagatsu, A. Tanaka, E. Tsukamoto, and N. Tamaki, Nucl. Med. Biol., 2002, 29, 345.
-
(2002)
Nucl. Med. Biol.
, vol.29
, pp. 345
-
-
Nishijima, K.1
Kuge, Y.2
Seki, K.3
Ohkura, K.4
Motoki, N.5
Nagatsu, K.6
Tanaka, A.7
Tsukamoto, E.8
Tamaki, N.9
-
8
-
-
4243055078
-
-
K. Nishijima, Y. Kuge, K. Seki, K. Ohkura, K. Morita, K. Nakada, and N. Tamaki, Nucl. Med. Commun., 2004, 25, 845.
-
(2004)
Nucl. Med. Commun.
, vol.25
, pp. 845
-
-
Nishijima, K.1
Kuge, Y.2
Seki, K.3
Ohkura, K.4
Morita, K.5
Nakada, K.6
Tamaki, N.7
-
9
-
-
33745220751
-
-
K. Ohkura, K. Nishijima, K. Sanoki, Y. Kuge, N. Tamaki, and K. Seki, Tetrahedron Lett., 2006, 47, 5321.
-
(2006)
Tetrahedron. Lett.
, vol.47
, pp. 5321
-
-
Ohkura, K.1
Nishijima, K.2
Sanoki, K.3
Kuge, Y.4
Tamaki, N.5
Seki, K.6
-
10
-
-
85044707286
-
-
K. Seki, K. Nishijima, Y. Kuge, N. Tamaki, L.I. Wiebe, and K. Ohkura, J. Pharm. Pharmceut. Sci., 2007, 10, 212.
-
(2007)
J. Pharm. Pharmceut. Sci.
, vol.10
, pp. 212
-
-
Seki, K.1
Nishijima, K.2
Kuge, Y.3
Tamaki, N.4
Wiebe, L.I.5
Ohkura, K.6
-
11
-
-
2942608177
-
-
S. Yano, H. Kazuno, T. Sato, N. Suzuki, T. Emura, K. Wierzba, J. Yamashita, Y. Tada, Y. Yamada, M. Fukushima, and T. Asao, Bioorg. Med. Chem., 2004, 12, 3443.
-
(2004)
Bioorg. Med. Chem.
, vol.12
, pp. 3443
-
-
Yano, S.1
Kazuno, H.2
Sato, T.3
Suzuki, N.4
Emura, T.5
Wierzba, K.6
Yamashita, J.7
Tada, Y.8
Yamada, Y.9
Fukushima, M.10
Asao, T.11
-
12
-
-
79751501909
-
-
3: C, 33.24; H, 3.14; N, 19.38. Found: C, 33.33; H, 3.09; N, 19.39
-
3: C, 33.24; H, 3.14; N, 19.38. Found: C, 33.33; H, 3.09; N, 19.39.
-
-
-
-
13
-
-
79751507241
-
-
3: 247.0412. Found: 247.0421
-
3: 247.0412. Found: 247.0421.
-
-
-
-
15
-
-
79751506072
-
-
11C nuclear reaction on nitrogen containing hydrogen 5% in an aluminum target. Bombardment was performed using a 20 μA beam of 18 MeV protons for 20 min
-
11C nuclear reaction on nitrogen containing hydrogen (5%) in an aluminum target. Bombardment was performed using a 20 μA beam of 18 MeV protons for 20 min.
-
-
-
-
16
-
-
79751511669
-
-
2 was bubbled with helium flow into a reaction vial containing a solution of 1a 1 mg in t-BuOH 0.5 mL in the presence of t-BuOK at 30 °C for 1min. The reaction mixture was subjected to reverse-phase HPLC equipped with UV monitor and radio detector: Megapak CIL C18, 25 cm × 1.0 cm i.d., 10% EtOH in water containing phosphoric acid pH 2.32, flow rate 5.0 mL/min
-
2 was bubbled with helium flow into a reaction vial containing a solution of 1a (1 mg) in t-BuOH (0.5 mL) in the presence of t-BuOK at 30 °C for 1min. The reaction mixture was subjected to reverse-phase HPLC equipped with UV monitor and radio detector: Megapak CIL C18, 25 cm × 1.0 cm i.d., 10% EtOH in water containing phosphoric acid (pH 2.32), flow rate 5.0 mL/min.
-
-
-
|